ICPT - インタ―セプト・ファ―マシュ―ティカルズ （Intercept Pharmaceuticals Inc.） インタ―セプト・ファ―マシュ―ティカルズICPTのチャート
ICPTの企業情報
| symbol | ICPT |
|---|---|
| 会社名 | Intercept Pharmaceuticals Inc （インタ―セプト・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 インターセプト・ファーマシューティカルズ(Intercept Pharmaceuticals Inc.)は胆汁酸化学を利用して、慢性肝疾患を治療する治療薬の開発と商業化を中心とするバイオ医薬品会社。同社の製品候補である｢オベチコール酸(OCA)｣は、天然に存在するヒトの胆汁酸に基づく構造を有する化学物質である胆汁酸アナログ。同社は不十分な応答を持っている患者、またはケア治療の標準を容認することができないため、追加的な治療を必要とする患者のための二次治療として、原発性胆汁性肝硬変（PBC）のために最初に｢OCA｣を開発している。 同社はPOISE試験と呼ばれるPBCでOCAの第Ⅲ相臨床試験を行い、POISE試験は米国と欧州で規制当局の承認を求めるための基礎となる。平成24年12月19日現在、同社は217人の患者とPOISE試験への登録を完了した。 インタ―セプト・ファ―マシュ―ティカルズは、米国のバイオ医薬品メ―カ―。独自の胆汁酸化学を利用し、慢性の肝臓疾患を治療する薬品の開発、商品化に注力する。同社の製品候補オベチコ―ル酸(OCA)は、胆汁酸に類似した化学物質であり、原発性胆汁性肝硬変のために開発、反応の低い患者などの治療として使われる。米国全土の消費者を対象に、事業を展開。 Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. |
| 本社所在地 | 10 Hudson Yards 37th FL New York NY 10001 USA |
| 代表者氏名 | Paolo Fundaro パオロ・ファナロ |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 646-747-1000 |
| 設立年月日 | 37500 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2012年 |
| 従業員数 | 507人 |
| url | www.interceptpharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/icpt |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -311.21800 |
| 終値（lastsale） | 108.02 |
| 時価総額（marketcap） | 3193577165.68 |
| 時価総額 | 時価総額（百万ドル） 2829.932 |
| 売上高 | 売上高（百万ドル） 158.55900 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 2654.894 |
| 当期純利益 | 当期純利益（百万ドル） -340.65600 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Intercept Pharmaceuticals Inc revenues increased 53% to $79.5M. Net loss decreased 11% to $156.8M. Revenues reflect Licensing revenue increase of 36% to $1.2M. Lower net loss reflects Stock-based Compensation in R&D decrease of 26% to $7M (expense) Other income net increase of 44% to $3.5M (income) General_Administrative decrease of 1% to $108.3M (expense). |
ICPTのテクニカル分析
ICPTのニュース
Drug pricing watchdog raises alarm over upcoming liver disease meds 2023/05/29 19:00:00 Seeking Alpha
The influential U.S. drug pricing watchdog ICER has warned about cost of future NASH drugs from Madrigal Pharma (MDGL) and Intercept Pharma (ICPT). Read more here.
Intercept Pharmaceuticals (NASDAQ:ICPT) Price Target Cut to $14.00 by Analysts at Bank of America 2023/05/24 08:10:41 The AM Reporter
Intercept Pharmaceuticals (NASDAQ:ICPT – Get Rating) had its target price decreased by Bank of America from $17.00 to $14.00 in a research note published on Tuesday morning, The Fly reports. A number of other research analysts have also weighed in on ICPT. Royal Bank of Canada upped their price objective on Intercept Pharmaceuticals from $17.00 […]
The Rising Challenge for Intercept Pharmaceuticals: Analyst Downgrade Amid Ocaliva''s DILI Concerns 2023/05/23 18:53:39 Benzinga
Canaccord Genuity has lowered the price target for Intercept Pharmaceutical Inc (NASDAQ: ICPT ) from $26 to $12, with a Hold rating . The analyst says Ocaliva, for PBC, is worth $16 per share, with OCA in NASH costing $4 based on overhead allocation for the rest of 2023 as it sees the program winding down. The FDA has concerns about drug-induced liver injury (DILI) that could be fatal. Related: What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept''s ''OCA In NASH … Full story available on Benzinga.com
Intercept Pharma Slips 28% As FDA Panel Votes Against Liver Disease Drug 2023/05/22 20:43:21 EIN News Pharmaceuticals
Intercept Pharmaceutics , Inc (ICPT) shares are down … . The FDA''s Gastrointestinal Drugs Advisory Committee (GIDAC) voted 12 …
Intercept crashes 29% after FDA AdCom snub for liver disease therapy 2023/05/22 17:42:11 Seeking Alpha
Intercept Pharma (ICPT) fell ~28% Monday after a group of independent experts at the FDA declined to endorse its liver disease drug obeticholic acid. Read more here.
Intercept cuts debt further with deal to exchange convertible debt (NASDAQ:ICPT) 2022/09/02 12:15:00 Seeking Alpha
Intercept Pharmaceuticals (ICPT), a biotech focused on liver diseases, announced privately negotiated exchange agreements on Friday to repurchase nearly $44.5M worth of convertible debt…
Intercept Pharmaceuticals Inc. (ICPT): Why Is The Stock Strong? 2022/08/31 12:00:00 Marketing Sentinel
Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) has a beta value of 1.26 and has seen 1.52 million shares traded in the last trading session. The company, currently valued at $509.08M, closed the last trade at $16.28 per share which meant it lost -$2.3 on the day or -12.38% during that session. The ICPT stock price is -30.53% … Intercept Pharmaceuticals Inc. (ICPT): Why Is The Stock Strong? Read More »
Intercept Pharmaceuticals Inc. (ICPT) is an excellent investment, but the stock is overvalued/undervalued right now 2022/08/29 13:16:00 US Post News
A share of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) closed at $18.02 per share on Friday, down from $18.91 day before. While Intercept Pharmaceuticals Inc. has underperformed by -4.71%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ICPT rose by 34.48%, with highs and lows ranging from $21.25 […]
Intercept Pharmaceuticals PT Lowered to $28 at B.Riley 2022/08/22 12:02:01 Investing.com
https://www.investing.com/news/pro/intercept-pharmaceuticals-pt-lowered-to-28-at-briley-432SI-2877438
Intercept Pharmaceuticals Settles Ocaliva Patent Litigation Case, With Dr Reddy''s 2022/08/19 07:02:06 Goodreturns
Intercept Pharmaceuticals Inc has said it entered into a settlement agreement with Dr Reddy''s Laboratories resolving the previously disclosed patent litigation to market a generic version of Ocaliva (obeticholic acid) 5 mg and 10 mg tablets in the USA. Ocaliva is
Intercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva for PBC Outside the U.S. 2022/07/01 20:01:00 Wallstreet:Online
MORRISTOWN, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the transaction between Intercept and Advanz Pharma announced on May 5, 2022, has now closed. As a result of this transaction, Intercept’s
Intercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva® for PBC Outside the U.S. 2022/07/01 20:01:00 GlobeNewswire
MORRISTOWN, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the transaction between Intercept and Advanz Pharma announced on May 5, 2022, has now closed. As a result of this transaction, Intercept’s international business has been divested and its international commercial and medical infrastructure have transitioned to Advanz Pharma.
Given A -64.9% Drop From High, Can Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) Quickly Recover? 2022/06/25 13:00:00 Marketing Sentinel
During the last session, Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)’s traded shares were 0.76 million, with the beta value of the company hitting 1.44. At the end of the trading day, the stock’s price was $13.56, reflecting an intraday gain of 0.22% or $0.03. The 52-week high for the ICPT share is $22.36, that puts it down … Given A -64.9% Drop From High, Can Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) Quickly Recover? Read More »
Intercept Announces PBC Data Presentations at The International Liver Congress 2022 2022/06/21 11:30:00 Wallstreet:Online
MORRISTOWN, N.J., June 21, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that multiple abstracts highlighting the benefits of obeticholic acid (OCA) in individuals with primary biliary cholangitis (PBC) will be
Intercept Pharmaceuticals Inc. (ICPT): Significant Improvements, Worth Being Considered 2022/06/11 12:30:00 Stocks Register
Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) concluded the trading at $12.68 on Friday, June 10, with a fall of -4.88% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $13.33 and 5Y monthly beta was reading 1.35 with its price kept floating in the … Intercept Pharmaceuticals Inc. (ICPT): Significant Improvements, Worth Being Considered Read More »